Neuromodulation Devices: World Market Prospects 2011-2021

02 Dec 2011 • by Natalie Aster

The US accounted for more than 88% of the global SCS market in 2010, according to Visiongain estimates. An increasing number of spinal surgery procedures have driven growth in this market. In the US, SCS is most commonly used in failed back surgery syndrome (FBSS), which is the persistent or recurrent pain felt by patients after successful spinal surgery. According to industry estimates, about 40% of patients who undergo spinal surgery are affected by FBSS. Also, predictions from leading pain societies across the USA have stated that approximately 20% of adult Americans experience chronic pain (equating to more than 60 million individuals). This statistic will further drive the SCS devices market in the US.

Report Details:

Neuromodulation Devices: World Market Prospects 2011-2021
Published: October 2011
Pages: 127
Price: US$ 2,664.00

Report Sample Abstract

Medtronic Dominated the US SCS Devices Market, Closely Followed by SJM and Boston Scientific

Medtronic is the market leader in the US SCS market, accounting for 38.5% of the total US sales in 2010. According to analyses, Medtronic generated $370m from sales of its SCS devices in the US. SJM followed closely behind Medtronic with market share of 31.5%, followed by Boston Scientific with 30.0%.

Market Shares (%) of Leading Companieas in the US SCS Devices Market, 2010

Source: Visiongane 2011

More information can be found in the report “Neuromodulation Devices: World Market Prospects 2011-2021” by Visiongain.

To order the report or ask for sample pages contact


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970